Micronutrients include electrolytes, minerals, vitamins, and carotenoids, and are required in microgram or milligram quantities for cellular metabolism. The liver plays an important role in micronutrient metabolism and this metabolism often is altered in chronic liver diseases. Here, we review how the liver contributes to micronutrient metabolism; how impaired micronutrient metabolism may be involved in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), a systemic disorder of energy, glucose, and lipid homeostasis; and how insights gained from micronutrient biology have informed NAFLD therapeutics. Finally, we highlight some of the challenges and opportunities that remain with investigating the contribution of micronutrients to NAFLD pathology and suggest strategies to incorporate our understanding into the care of NAFLD patients. (Cell Mol Gastroenterol Hepatol 2018;6:451–462; https://doi.org/10.1016/j.jcmgh.2018.07.004)

Keywords: NAFLD; Obesity; Micronutrients; Vitamins; minerals; carotenoids.

Nonalcoholic fatty liver disease (NAFLD) is a systemic disorder of energy, glucose, and lipid homeostasis with hepatic manifestations. Patients with NAFLD have perturbations of central signals involved in satiety and preference that result in excess consumption of largely obesogenic macronutrients (reviewed by Carr et al.), as well as deranged energy balance that may result in part from polymorphisms in metabolic regulatory genes. The constellation of this dysregulation of energy balance ultimately results in the accumulation of lipids within hepatocellular lipid droplets, the onset of which predisposes patients to nonalcoholic steatohepatitis (NASH), NASH fibrosis, and cirrhosis. NAFLD differentially impacts racial/ethnic groups (with the highest prevalence observed in Hispanics), and the burden of NAFLD parallels that of obesity (defined as having a body mass index [BMI] ≥ 30). Indeed, both NAFLD and obesity prevalence are estimated to affect at least 40% of US adults. Although nonobese patients can develop NAFLD, and, conversely, some obese patients appear to be protected from NAFLD based on currently defined cut-off values for intrahepatic triglyceride levels, most data support an intersection between NAFLD and obesity pathogenesis. Specifically, the majority of patients with NAFLD and obesity have a relative deficit in energy expenditure and disturbances in lipid and glucose homeostasis (ie, insulin resistance) resulting from excess macronutrient intake. In NAFLD, some of these macronutrients (eg, sucrose and fructose) cause direct injury to the small intestinal wall epithelium. Such epithelial injury leads to translocation of bacterial products that increase portal plasma lipopolysaccharide concentrations. The resultant hepatic Toll-like receptor 4 activation leads to tumor necrosis factor-α up-regulation, steatosis, and inflammation. Coupled with the onset of an insulin-resistant state (including the dysregulation of the glucose homeostatic adipokines, adiponectin and leptin), these factors are considered key components of NAFLD pathogenesis.

Although the pathogenic role of macronutrients is well established in both NAFLD and obesity, the contribution of micronutrients to NAFLD pathogenesis has garnered less attention than with obesity. Nevertheless, micronutrients in NAFLD play an important role. This review uses insights gained from obesity to explore the mechanisms by which micronutrients contribute to NAFLD pathogenesis and establish the basis for the therapeutic targeting of micronutrients in NAFLD patients.

Micronutrient Definition

Micronutrients are defined as nutrients that are needed in only microgram or milligram quantities for physiologic functions as defined by the World Health Organization. Micronutrients include electrolytes, minerals, vitamins, and carotenoids, and are required for enzymatic activity, intermediary metabolism, and metabolic response to illness. Electrolytes (ie, sodium, chloride, and potassium) and minerals (eg, calcium, phosphorus, zinc, and so forth) are inorganic compounds required for tissue structure, pH regulation, neuronal signaling, muscle contraction, and...
enzy matic activities. Electrolytes also can be associated with minerals to confer activities. Although the role of electrolyte homeostasis is not well established in NAFLD (with the exception of an epidemiologic association between high-sodium diets and NAFLD prevalence), the contribution of several minerals, vitamins, and carotenoids to the pathogenesis of NAFLD increasingly is being appreciated.

Minerals are inorganic compounds that share many of the basic functions of electrolytes. Minerals form salts with other elements or bind to organic compounds while maintaining their own chemical identity. Minerals are classified into major or trace minerals depending on their tissue concentration of greater than or less than 5 g, respectively. Examples of major minerals include calcium, phosphorus, and magnesium; and some minor minerals include zinc, copper, iron, and iodine.

Vitamins are organic compounds that regulate cellular growth and metabolism, and their solubility into either lipids or water determines the mechanisms by which they are absorbed, transported, stored, and excreted. After small intestinal absorption, fat-soluble vitamins (vitamins A, D, E, and K) are transported through the lymphatic system via chylomicrons and stored in liver and adipose tissues, whereas water-soluble vitamins (thiamin, riboflavin, niacin, vitamin B₆, folate, vitamin B₁₂, pantothenic acid, biotin, and vitamin C) enter the bloodstream, existing only in trace amounts in tissues before being excreted in urine. These differences in tissue reserves between fat- and water-soluble vitamins translate to differences in daily consumption requirements to maintain physiologic levels. Namely, daily intake of fat-soluble vitamins is not required whereas daily consumption of water-soluble vitamins is essential.

Carotenoids are a large class of phytochemicals with anti-inflammatory and anti-inflammatory activity. This class includes carotenes (eg, α-carotene, β-carotene, and lycopene) and xanthophylls (eg, lutein, zeaxanthin, β-cryptoxanthin, and astaxanthin). They largely are found in fruits and vegetables, but also are found in smaller concentrations in poultry. Because several carotenoids can be converted to vitamin A, carotenoids have additional roles in cellular development, growth, and differentiation. The majority of this conversion occurs in the intestine and is impaired in obese individuals, thus linking carotenoid metabolism indirectly with NAFLD pathogenesis.

The Liver and Micronutrient Metabolism

The liver plays a critical role in micronutrient metabolism. The liver is involved in the transport and storage of many micronutrients such as vitamin A, vitamin B₁₂, and copper. In fact, the majority of the body’s vitamin A stores are found in the stellate cells of the liver. In addition, as the body’s major site of protein synthesis, the liver produces binding, transport, and regulatory proteins that are required for micronutrient homeostasis. For example, zinc and other micronutrients are found bound to albumin. Thus, zinc deficiency is linked directly to hypoalbuminemia, which occurs as a result of hepatic synthetic dysfunction. Furthermore, the protein metallothionein is in part synthesized in the liver and functions as a metal chelator and transport protein. The liver also synthesizes bile (a process regulated in part through the bile acid nuclear receptor farnesoid X receptor FXR). Bile is needed for fat emulsification and absorption of fat-soluble vitamins, and, in turn, fat-soluble vitamins regulate their own absorption through regulating hepatic bile acid synthesis (Figure 1).

Micronutrients in NAFLD

The aforementioned derangements in energy and nutrient homeostasis in NAFLD patients are sufficient to cause hepatic steatosis. However, the specific factors that promote progression from steatosis to advanced stages of NAFLD (ie, NASH, NASH fibrosis, and cirrhosis) remain unknown. Emerging data suggest that the hepatocellular accumulation of bioactive lipids causes hepatocellular lipotoxicity and oxidative stress through the accumulation of reactive oxygen species (ROS). The ensuing inflammatory and fibrogenic responses from nonparenchymal cells exacerbate liver injury and impair hepatic function.

Zinc and NAFLD

Despite data suggesting mineral deficiencies in NAFLD patients, most data do not support insufficient mineral consumption as a possible mechanism for these deficiencies, except in the case of zinc deficiency. Other than inadequate intake, the mechanism of zinc deficiency in NAFLD patients is unknown. In an obesogenic mouse model using sucrose feeding, mice fed a normal diet supplemented with sucrose have lower serum zinc levels than mice fed a regular diet. Compared with sucrose-fed mice, zinc-supplemented sucrose-fed mice have higher levels of the satiety and energy homeostatic adipokine leptin, despite similar body weight and fat mass. Compared with lean C57BL/6J mice, obese leptin-deficient ob/ob mice have higher plasma zinc levels but lower hepatic zinc content. Together, these studies suggest an inverse relationship between hepatic zinc content and plasma zinc levels, and also a mechanistic (albeit ill-defined) link between zinc and leptin. Clues to this relationship may exist by understanding how the ratio of free to bound zinc relates to both leptin and
hepatic zinc levels and in further dissecting zinc’s known glucose lowering and hepatic glucose regulatory effects. Zinc deficiency may augment oxidative stress in NAFLD as seen in a rodent model of experimental alcoholic liver disease, a related condition of hepatic lipid dysregulation. In this model, zinc reduces hepatic triglyceride accumulation and oxidative stress through enhanced very low density lipoprotein secretion and peroxisome proliferator activated receptor-α and hepatocyte nuclear factor-4α–mediated augmentation of fatty acid oxidation. Such effects of zinc on lipotoxicity-induced oxidative stress are suggested further by the 20% reduction in malondialdehyde observed in high-fat diet–fed Sprague–Dawley rats co-supplemented with zinc and selenium. In addition to the putative effects on oxidative stress, zinc deficiency also may exacerbate NAFLD fibrosis and cirrhosis. Cirrhosis can result in impaired ammonia clearance, a condition remedied by zinc supplementation in a carbon tetrachloride rat model of fibrosis.

**Figure 1. Micronutrients and the liver in NAFLD.** Hepatic contribution to metabolism of the micronutrients involved in NAFLD pathogenesis. Vit., vitamin.

**Table 1. Putative Hepatocellular Mechanisms of Micronutrients in NAFLD**

| Micronutrient | Serum levels in NAFLD | Possible mechanism | NAFLD therapeutic | Referenced studies |
|---------------|-----------------------|-------------------|-------------------|-------------------|
| Zinc          | ↓                     | A, L, F           | X                 | 56–59             |
| Copper        | ↓                     | A, L              | X                 | 64, 66            |
| Iron          | ↑                     | L, I              | Phlebotomy        | 70, 79, 80        |
| Vitamin A     | ↓                     | L                 | X                 | 85–87             |
| Vitamin D     | ↓↑                    | A, L, F, I        | X                 | 106, 107          |
| Vitamin E     | ↓                     | A, L, F           | 800 IU vitamin E daily | 110–116          |
| Carotenoids   | ↓                     | A, L, F, I        | X                 | 122, 123, 125, 126 |

**NOTE.** Putative mechanisms of micronutrients in NAFLD pathogenesis and attempts at targeting micronutrients therapeutically in NAFLD. A, antioxidant; F, antiﬁbrotic; I, immune effects; L, lipoprotective; X, no therapeutics exist.
Copper and NAFLD

The liver has a critical role in copper metabolism, including in the production of the copper transport protein ceruloplasmin. In Sprague–Dawley and leptin-receptor–deficient Zucker (fa/fa) rats fed a copper-depleted, copper-enriched, or normal diet for 8 weeks, copper deficiency caused severe hepatic steatosis and increased liver weight. Serum ceruloplasmin levels mirror copper patterns and low ceruloplasmin levels are associated with advanced liver disease in children and adults. Copper exerts a myriad of effects in the liver including on anti-oxidant and cellular respiratory systems. In the liver, copper is a co-factor for several anti-oxidant enzymes. For example, in isolated Sprague–Dawley rat livers, copper deficiency causes oxidative stress and a presumed counter-regulatory transcriptional up-regulation of the anti-oxidant enzyme superoxide dismutase. Furthermore, copper deficiency in Sprague–Dawley weanling rats promotes hepatic fatty acid synthesis and assembly into triacylglycerols and phospholipids. Consequently, copper deficiency in NAFLD patients may exacerbate oxidative stress and lipotoxicity from both impaired mitochondrial function and up-regulation of triglyceride synthetic pathways. In NAFLD patients, serum and/or hepatic copper levels are up to 50% lower than in control patients or those with other liver diseases. Low hepatic copper is associated with more advanced liver disease, systemic metabolic disease, and diabetic status. These studies must be considered in the context of both macronutrient (ie, fructose) inhibitory effects on copper absorption and challenges in measuring hepatic copper in the steatotic liver.

Iron and NAFLD

The earlier-mentioned minerals have been implicated in NAFLD pathogenesis largely owing to serum and/or hepatic deficiencies, however, the contribution of iron to NAFLD is most widely accepted to be owing to iron excess. Excess iron correlates with hepatic lipid peroxidation and NAFLD severity. The iron regulatory protein hepcidin is a hormone produced by the liver that regulates iron absorption from enterocytes by causing internalization of the basal membrane iron transporter ferroportin. Ferroportin is expressed in multiple tissues but the enterocyte ferroportin is considered the major driver of iron hemostasis. Hepcidin, ferroportin, ferritin (the storage form of iron), and iron itself all have been associated with hepatic injury in NAFLD. In patients with NAFLD, genetic mutations and polymorphisms affecting hepcidin’s regulation of ferroportin-mediated iron absorption may result in either increased hepatic iron content (in the case of genetic hemochromatosis) or reduced hepatic iron content (in the case of the VV genotype of the transmembrane protease serine-6 gene). Based on a large study involving patients who participated in studies of the NASH Clinical Research Network, hyperferritinemia is an independent predictor of NASH fibrosis. These results are consistent with data showing an association between hepatic iron content and NAFLD severity, albeit the specific hepatic iron depot is debated. Excess hepatic iron in the liver may impair hepatic lipid homeostatic and immune functions. In leptin-resistant db/db mice fed an iron-rich diet, hepatocellular ballooning (the signature histologic feature of NASH diagnosis) was observed in 85% of the mice. In addition, iron-fed mice have increased levels of malonyldialdehyde, inflammasome and immune cell markers, and inflammatory cytokines. These effects of iron on nonparenchymal cells are supported further by data by Malik et al showing an association between increased apoptosis and iron accumulation in hepatic reticuloendothelial cells in NAFLD patients. Whether iron is involved directly in the cascade of events that cause NAFLD progression remains unclear because results of phlebotomy trials in NAFLD patients are equivocal.

Vitamin A and NAFLD

Compared with both nondiabetic and diabetic non-NAFLD patients, patients with NAFLD have lower serum levels of retinoic acid, a metabolite of vitamin A. Retinoic acid deficiency worsens with progressive NAFLD, and the serum level of retinoic acid negatively correlates with both intrahepatic triglyceride content and transaminase levels. This relationship between retinoid acid and hepatic triglyceride content suggests that vitamin A (most of which is stored in the liver) has a role in overall hepatic lipid metabolism, not only in stellate cell function. Indeed, retinoic acid binds the retinoid X receptor, a nuclear hormone receptor that heterodimerizes with peroxisome proliferator activated receptor-α, a key hepatic fatty acid β-oxidative regulator, and in so doing regulates hepatic lipid metabolism. In support of this link between retinoid acid deficiency and impaired hepatic lipid metabolism, transgenic mice that lack hepatic expression of retinoic acid develop steatohepatitis predominantly owing to defects in mitochondrial β-oxidation, effects that can be reversed by a high-retinoid-acid diet.

B Vitamins and NAFLD

There are 8 B vitamins, but only vitamins B3 (niacin) and B12 have been examined in NAFLD patients. Vitamin B3 has roles in cellular lipid biology, while B12 has roles in DNA synthesis and modification and mitochondrial metabolism. It is likely that initial investigations of vitamin B3 in NAFLD stemmed from the known protective role of niacin supplementation in cardiovascular health and cardiovascular oxidative stress. In Sprague–Dawley rats fed a high-fat diet to induce NAFLD, addition of niacin after NAFLD induction significantly reduced both hepatic and serum triglyceride levels, ameliorated hepatic steatosis, and reduced hepatic lipid peroxidation as measured by thiobarbituric acid–reactive substances. Because this was not a model of steatohepatitis, the lack of a change in inflammatory markers by niacin is of unclear significance. The anti-inflammatory action of niacin has been established in vitro with palmitate-incubated Hep G2 cells and primary human hepatocytes. Co-incubation with niacin not only reduces lipid accumulation owing to down-regulation of the
triglyceride synthetic enzyme diacylglycerol acyltransferase 2, but also reduces ROS production, reduced nicotinamide adenine dinucleotide phosphate oxidase activity (a ROS enzyme), and interleukin (IL)8 inflammatory cytokine levels. These in vitro results are consistent with human data showing a diacylglycerol acyltransferase 2 polymorphism dose-dependent effect of niacin supplementation on hepatic fat, plasma triglycerides, and body weight reduction. Specifically, patients with the T allele experience an approximately 60% reduction in hepatic fat while those with 2 copies of the variant C allele have only a 25% reduction in hepatic fat. Unlike NAFLD-relevant studies that show reduced B2 levels, studies with vitamin B12 are circumstantial at best because serum B12 levels in NAFLD patients are either unchanged or modestly reduced.

**Vitamin C and NAFLD**

Vitamin C and other anti-oxidants balance the effects of ROS in cells by scavenging free radicals. In NAFLD, this scavenging mechanism may protect cells from lipotoxicity-induced cellular oxidative stress. Low vitamin C levels are associated modestly with biopsy-proven NASH in children, but in adults there appears to be no association. Besides attempts to use vitamin C therapeutically in NAFLD there are no experimental studies in NAFLD directed toward understanding how vitamin C deficiency promotes hepatic injury in NAFLD.

**Vitamin D and NAFLD**

Vitamin D intake is estimated to be 50% lower in NAFLD patients than in non-NAFLD patients, and low vitamin D levels are associated with incident liver disease risk (some of whom develop NAFLD). Levels of vitamin D have been associated inconsistently with NAFLD, NAFLD severity, and insulin resistance, a condition commonly shared by both obese and NAFLD patients. In addition, several genes involved in vitamin D metabolism have shown no differential regulation in NAFLD patients compared with controls. Nevertheless, the putative effects of vitamin D on hepatic biology are provocative. Namely, vitamin D deficiency exacerbates experimental NASH. Sprague–Dawley rats fed a Western diet deficient in vitamin D have pronounced steatohepatitis compared with dietary controls. In addition, pathways involved in oxidative stress (eg, heme oxygenase) and inflammation (eg, IL6, IL4, and IL1β) by way of Toll-like receptor signaling are up-regulated in the absence of vitamin D, thus linking vitamin D metabolism with both NAFLD lipotoxicity and the liver’s pathogenic response to gut translocation of microbial products.

Vitamin D also reduces secretion of fibrogenic growth factors (including transforming growth factor [TGF]β and α-smooth muscle actin) from primary human hepatic stellate cells. The antifibrotic effect of vitamin D is dependent on both the genotype of the vitamin D receptor and vitamin D receptor levels because vitamin D fails to inhibit the TGFβ-induced fibrogenic program in vitamin D–receptor–deficient stellate cells. It is perhaps this effect of vitamin D–receptor polymorphisms that partially explains the inconsistent results regarding the relationship of vitamin D levels to NAFLD severity.

**Vitamin E and NAFLD**

Plasma levels of vitamin E are reduced in patients with biopsy-proven NASH compared with healthy patients. There is also a trend toward lower hepatic vitamin E levels in NAFLD patients compared with control patients. In experimental models, vitamin E has antisteatotic, anti-inflammatory, and antifibrotic effects. Effects on steatosis may in part be owing to vitamin E’s inhibitory effect on hepatocyte fatty acid uptake. Namely, in guinea pigs fed an obesogenic diet, vitamin E prevents the up-regulation of the hepatic fatty acid receptor CD36. The reduced hepatocellular uptake of circulating lipids reduces the intracellular pool of lipids available for lipid peroxidation. By using mice fed a methionine-choline–deficient diet (a steatohepatitis experimental model), Nan et al showed that the reduction in liver enzyme levels, steatosis, and inflammation was associated with down-regulation of genes involved in lipid peroxidation and inflammation. Although not measured directly in their study, it is likely that this down-regulation lead to reduced concentrations of hepatic malonylaldelhyde (a product of phospholipid peroxidation), as shown in high-fat diet–fed Sprague–Dawley rats and high-carbohydrate diet–fed ob/ob mice supplemented with vitamin E.

In addition to protective effects on lipid peroxidation, vitamin E has antifibrotic effects. In a model of advanced fibrosis (albeit not a NAFLD model), rats subjected to intraperitoneal carbon tetrachloride injections had reduced lipid peroxidation, inflammation, and fibrosis when co-administered vitamin E. Congruent with those findings was the observation that vitamin E down-regulates Col1A2 expression in cultured rat hepatic stellate cells that overexpress Cyp2E1. These beneficial effects of vitamin E on remodeling are partially through the down-regulation of hepatic TGFβ1 and procollagen genes. This constellation of hepatoprotective effects of vitamin E established the basis for its therapeutic use in NASH.

**Carotenoids and NAFLD**

Plasma levels of several carotene and xanthophyll carotenoids are lower in biopsy-proven NASH patients than in controls independent of BMI and liver enzyme levels. In addition, not only are serum carotenoid levels associated inversely with NAFLD prevalence and liver enzyme levels, but also a large prospective study of 2687 NAFLD subjects showed that serum carotenoid levels are associated with NAFLD improvement thus positioning carotenoids as potential therapeutic targets.

The potential of carotenoids as NAFLD targets is supported by evidence in high-fat diet–fed rats in whom β-carotene supplementation reduced liver weight and liver enzyme levels. β-carotene also reduced lipid peroxidation as measured by thiobarbituric acid–reactive substances and reduced oxidative stress by increasing levels of the anti-
oxidant superoxide dismutase. In addition, in a mouse model of diet-induced NASH, β-cryptoxanthin supplementation reduced hepatic steatosis, steatohepatitis, lipid peroxidation, and fibrosis, likely owing to the down-regulation of lipid synthetic genes established by DNA microarray analysis. In fact, β-cryptoxanthin supplementation modulates the expression of more than 500 genes, including the down-regulation of genes involved in immune cell trafficking and tumor necrosis factor-α signalling, the latter of which is a key mediator of NASH. In a follow-up study by the same investigators, β-cryptoxanthin was found to accumulate predominantly in the liver and reduce steatosis, steatohepatitis, and fibrosis via down-regulation of lipogenic and fibrogenic genes, enhanced lipolysis, and reduced infiltration and activation of Kupffer cells. Furthermore, β-cryptoxanthin supplementation ameliorated NASH progression and improved glucose tolerance and insulin resistance.

Similar to β-cryptoxanthin, astaxanthin exerts anti-steatotic effects on the liver in both genetic and diet-induced mouse models of NAFLD. In female ddY mice fed a high-fat diet, astaxanthin reduced liver triglyceride levels and liver weight in a dose-dependent manner. These changes in part were owing to increased fat utilization as shown by a lower respiratory exchange ratio in the astaxanthin-supplemented mice as compared with control mice. In a cholate-rich dietary model of NASH, astaxanthin reduced lipid peroxidation and expression of lipogenic genes and improved glucose tolerance and insulin sensitivity.

**Micronutrients as Therapeutic Targets**

Micronutrient biology only modestly has informed NAFLD therapeutics. For example, carotenoid supplementation has not been trialed in NAFLD patients despite some evidence of alanine aminotransferase (ALT) improvement in runners supplemented with the carotenoid-containing pequi fruit pulp oil. In addition, the majority of NASH patients fail to normalize vitamin D3 levels or liver histology in response to 6 months of a daily dose of 2000 IU of vitamin D3 supplementation. Perhaps more promising is the combination of daily 1000 mg vitamin C and vitamin E 1000 IU for 6 months, which modestly improved fibrosis scores in biopsy-proven NAFLD patients. Unfortunately, these results are tempered by the statistical weighting toward diabetic patients with fibrosis in the intervention group. Finally, to mitigate iron excess, phlebotomy has been used as a potential therapeutic strategy, but these small studies have shown either no or only mild benefit.

In contrast to the aforementioned micronutrient therapeutic attempts, vitamin E supplementation is a successful example of how micronutrients can be used to modulate NAFLD. The Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Non-alcoholic Steatohepatitis trial included 247 adult patients with biopsy-proven NASH who were randomized to receive 800 IU vitamin E, 40 mg pioglitazone, or placebo daily for 96 weeks. The primary end point was end-of-study histologic improvement. Compared with placebo, vitamin E supplementation improved liver enzyme levels and body weight. Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Non-alcoholic Steatohepatitis additionally established that vitamin E improved NASH steatosis and/or lobular inflammation in 43% of patients compared with 19% of patients who received placebo. Despite the proposed antiobfictive mode of action of vitamin E, there was no benefit of vitamin E supplementation in hepatic fibrosis reduction in adults.

In children, 800 IU vitamin E daily similarly improved NASH histology. The treatment of nonalcoholic fatty liver disease in children (TONIC) trial was a study of 173 children with biopsy-proven NAFLD who were randomized to receive 800 IU vitamin E, 1000 mg metformin, or placebo daily for 96 weeks. The primary outcome was a sustained reduction of ALT (a largely inconsistent end point in NAFLD patients). Fifty-eight percent of patients achieved NASH histologic resolution owing to improvement in inflammation scores. As seen with adults, there was no antiobfictive effect of vitamin E in children. Vitamin E supplementation now is approved for the clinical management of adult patients with NASH, but not for children because the TONIC study failed to meet its primary end point of ALT reduction.

**Conclusions**

Although excessive macronutrient intake contributes to both tissue injury and perturbations of energy homeostasis in NAFLD patients, micronutrients (either their deficiency or excess) may compound these insults by deregulating lipid homeostatic and anti-oxidant pathways. Understanding the role of micronutrients in NAFLD even may help improve our understanding of nonobese NAFLD. Dissecting the specific contributions of micronutrients, however, remains challenging because human diets are complex and fail to replicate experimental dietary models. In addition, serum levels of micronutrients reflect an intricate in vivo physiology that involves multiple organs, hormonal signals, and varied volumes of distribution. Consequently, serum laboratory values are only surrogate markers of hepatic micronutrient exposure. Nevertheless, the interaction of these nutrients with the hepatic intracellular and extracellular environments ultimately may prove critical to our understanding of how NAFLD patients advance from steatosis to steatohepatitis and fibrosis.

Reliable noninvasive biomarkers to establish NAFLD stage are elusive and, here too, micronutrients have a niche. For example, levels of ferritin and ceruloplasmin help prognosticate NAFLD disease severity, while vitamin A and D deficiencies suggest advanced liver disease in cirrhotic patients. We even eventually may uncover that circulating levels of these and other fat-soluble vitamins predict the efficacy of novel NAFLD therapies that target bile acid signaling, as in the case of FXR agonists. Could some of the metabolic benefit derived from FXR agonism result from alterations in micronutrient absorption and secondarily hepatic uptake? These and other questions represent new areas of investigation in micronutrient NAFLD pathogenesis. The dearth of data related to micronutrients in NAFLD patients as compared with our current understanding of
how macronutrients promote disease means that routine serum and hepatic measurement of micronutrients cannot be recommended (yet). Neither can hepatologists, gastroenterologists, and other providers recommend diets with specific micronutrient compositions. Still, we remain optimistic and predict that the current armamentarium of anti-obesity modalities will serve as a window for the future of NAFLD nutritional management. For now, it is our view that the best advice for NAFLD patients is to consume a nutritionally balanced but relatively energy-restricted diet that avoids exposure to processed foods and fructose-containing beverages, akin to a sodium-reduced version of a Mediterranean-style diet, which is high in fiber, rich in anti-oxidants, and improves BMI, insulin resistance, and hepatic steatosis.

References

1. Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am 2016;45:639–652.

2. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, Butler JL, Tomas M, Hoffmann U, Hwang SJ, Massaro JM, O’Donnell CJ, Sahani DV, Salomaa V, Schadt EE, Schwartz SM, Siscovick DS, Voight BF, Carr JJ, Feitosa MF, Harris TB, Fox CS, Smith AV, Kao WH, Hirschhorn JN, Borecki IB. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7, e1001324.

3. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461–1465.

4. Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, Liu Y, Kozlitina J, Stender S, Wood GC, Stepanchick AN, Still MD, McCarthy S, O’Dushlaine C, Packer JS, Balasubramanian S, Gosalia N, Esopi D, Kim SY, Mukherjee S, Lopez AE, Fuller ED, Penn J, Chu X, Luo JZ, Mirshahi UL, Carey DJ, Still CD, Feldman MD, Small A, Damrauer SM, Rader DJ, Zambrowicz B, Olson W, Murphy AJ, Borecki IB, Shuldiner AR, Reid JG, Overton JD, Yancovits GD, Hobbs HH, Cohen JC, Gottesman O, Teslovich TM, Baras A, Mirshahi T, Gromada J, Dewey FE. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 2018; 378:1096–1106.

5. Browing JD, Szczechanski LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387–1395.

6. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124–131.

7. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007–2008 to 2015–2016. JAMA 2018;319:1723–1725.

8. Margariti E, Deutsch M, Manolakopoulos S, Papatheodoridis GV. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol 2012;25:45–51.

9. Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: long-term follow-up study. Hepatol Commun 2018;2:48–57.

10. Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, Chan HL, Chim AM, Woo J, Chu WC, Wong VW. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 2015;110:1306–1314; quiz 1315.

11. Bril F, Portillo-Sanchez P, Liu IC, Kalavalapalli S, Dayton K, Cusi K. Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients. Diabetes Care 2018;41:187–192.

12. Foster T, Anania FA, Li D, Katz R, Budoff M. The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Dig Dis Sci 2013;58:2392–2398.

13. Zhou X, Han D, Xu R, Li S, Wu H, Qu C, Wang F, Wang X, Zhao Y. A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet. PLoS One 2014;9:e115148.

14. Bergheim I, Weber S, Vos M, Kramer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008;48:983–992.

15. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffmann HM, Flavell RA. Inflammammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179–185.

16. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009;50:1094–1104.

17. Ye D, Li FY, Lam KS, Li H, Jia W, Wang Y, Man K, Lo CM, Li X, Xu A. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012;61:1058–1067.

18. Sharifinia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peck RM Jr, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol 2015;309:G270–G278.

19. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957–969.

20. Garcia OP, Long KZ, Rosado JL. Impact of micronutrient deficiencies on obesity. Nutr Rev 2009;67:559–572.
21. Germand AD, Schulze KJ, Stewart CP, West KP Jr, Christian P. Micronutrient deficiencies in pregnancy worldwide: health effects and prevention. Nat Rev Endocrinol 2016;12:274–289.
22. Joint FAO/WHO Expert Consultation on Human Vitamin and Mineral Requirements and World Health Organization. Department of Nutrition for Health and Development. Vitamin and mineral requirements in human nutrition. 2nd ed. Geneva: World Health Organization, 2005.
23. Shenkin A. The key role of micronutrients. Clin Nutr 2006;25:1–13.
24. Choi Y, Lee JE, Chang Y, Kim MK, Sung E, Shin H, Ryu S. Dietary sodium and potassium intake in relation to non-alcoholic fatty liver disease. Br J Nutr 2016;116:1447–1456.
25. Kwok RM, Torres DM, Harrison SA. Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology 2013;58:1166–1174.
26. Dudek SG. Nutrition essentials for nursing practice. Philadelphia, PA, Lippincott Williams & Wilkins, Wolters Kluwer.
27. Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids. Ann N Y Acad Sci 1992;669:7–20.
28. Chen G, Ni Y, Nagata N, Xu L, Ota T. Micronutrient antioxidants and nonalcoholic fatty liver disease. Int J Mol Sci 2016;17.
29. Fat-soluble vitamins and micronutrients: Vitamins A and E and carotenoids. Available from: https://www.cdc.gov/nutritionreport/99-02/pdf/nr_ch2a.pdf. Accessed July 3, 2018.
30. Tang G. Bioconversion of dietary provitamin A carotenoids to vitamin A in humans. Am J Clin Nutr 2010;91:1468S–1473S.
31. Tang G, Qin J, Dolnikowski GG, Russell RM. Short-term (intestinal) and long-term (postintestinal) conversion of beta-carotene to retinol in adults as assessed by a stable-isotope reference method. Am J Clin Nutr 2003;78:259–266.
32. Blomhoff R, Green MH, Berg T, Norum KR. Transport and storage of vitamin A. Science 1990;250:399–404.
33. Saeed A, Dullaart RPF, Schreuder T, Blokzijl H, Faber KN. Disturbed vitamin A metabolism in non-alcoholic fatty liver disease (NAFLD). Nutrients 2017;10.
34. Hendriks HF, Verhoofstad WA, Brouwer A, de Leeuw AM, Knook DL. Perisinusoidal fat-storing cells are the main vitamin A storage sites in rat liver. Exp Cell Res 1985;160:138–149.
35. Blindauer CA, Harvey I, Bunyan KE, Stewart AJ, Sleep D, Harrison DJ, Berezenko S, Sadler PJ. Structure, properties, and engineering of the major zinc binding site on human albumin. J Biol Chem 2009;284:23116–23124.
36. Nagamine T, Nakajima K. Significance of metallothionein expression in liver disease. Curr Pharm Biotechnol 2013;14:420–426.
37. Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep 2015;17:500.
38. Schmidt DR, Holmstrom SR, Fon Tacer K, Bookout AL, Kliewer SA, Mangelsdorf DJ. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010;285:14486–14494.
39. Fuchs M, Sanyal AJ. Lipotoxicity in NASH. J Hepatol 2012;56:291–293.
40. Hirsova P, Gores GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol 2015;1:17–27.
41. de Luis DA, Pacheco D, Izuela O, Terroba MC, Cuellar L, Cabezas G. Micronutrient status in morbidly obese women before bariatric surgery. Surg Obes Relat Dis 2013;9:323–327.
42. Toh SY, Zarshenas N, Jorgensen J. Prevalence of nutrient deficiencies in bariatric patients. Nutrition 2009;25:1150–1156.
43. Sanchez A, Rojas P, Basfi-Fer K, Carrasco F, Inostroza J, Codoceo J, Valencia A, Papapietro K, Csendes A, Ruz M. Micronutrient deficiencies in morbidly obese women prior to bariatric surgery. Obes Surg 2016;26:361–368.
44. Li J, Cordero P, Nguyen V, Oben JA. The role of vitamins in the pathogenesis of non-alcoholic fatty liver disease. Integr Med Insights 2016;11:19–25.
45. Liu Y, Chen H, Wang J, Zhou W, Sun R, Xia M. Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease. Am J Clin Nutr 2015;102:130–137.
46. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol 2014;220:747–759.
47. de Oliveira C, de Mattos AB, Silva CB, Mota JF, Zemdegs JC. Nutritional and hormonal modulation of adiponectin and its receptors adipor1 and adipor2. Vitam Horm 2012;90:57–94.
48. Landrier JF, Gouranton E, El Yazidi C, Malezet C, Balague P, Borel P, Amiot MJ. Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Endocrinology 2009;150:5318–5325.
49. Zolfaghari H, Askari G, Siassi F, Feizi A, Sotoudeh G. Intake of nutrients, fiber, and sugar in patients with nonalcoholic fatty liver disease in comparison to healthy individuals. Int J Prev Med 2016;7:98.
50. Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hisa Y, Kawamura M, Ebihara K, Onji M. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007;23:46–52.
51. Da Silva HE, Arendt BM, Noureldin SA, Therapondos G, Guindi M, Allard JP. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Diet 2014;114:1181–1194.
52. Chen MD, Lin PY. Zinc-induced hyperleptinemia relates to the amelioration of sucrose-induced obesity with zinc repletion. Obes Res 2000;8:525–529.
53. Kennedy ML, Failla ML, Smith JC Jr. Influence of genetic obesity on tissue concentrations of zinc, copper, manganese and iron in mice. J Nutr 1986;116:1432–1441.
54. Jayawardena R, Ranasinghe P, Galappaththy P, Malkanthi R, Constantine G, Katulanda P. Effects of zinc
supplementation on diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 2012;4:13.
55. Brand IA, Kleineke J. Intracellular zinc movement and its effect on the carbohydrate metabolism of isolated rat hepatocytes. J Biol Chem 1996;271:1941–1949.
56. Carr RM, Correnti J. Insulin resistance in clinical and experimental alcoholic liver disease. Ann N Y Acad Sci 2015;1353:1–20.
57. Kang X, Zhong W, Liu J, Song Z, McClain CJ, Kang YJ, Zhou Z. Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Hepatology 2009;50:1241–1250.
58. Mousavi SN, Faghihi A, Motaghenejad M, Shiasi M, Imanparast F, Amirzadeh M, Shidfar F. Zinc and selenium co-supplementation reduces some lipid peroxidation and angiogenesis markers in a rat model of NAFLD-fed high fat diet. Biol Trace Elem Res 2018;181:288–295.
59. Riggio O, Merli M, Capocaccia L, Caschera M, Zullo A, Pinto G, Gaudio E, Franchitto A, Spagnoli R, D'Aquilino E, Seri S, Moretti R, Cantafora A. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992;16:785–789.
60. Aigner E, Strasser M, Haufe H, Sonnewerb T, Hohla F, Stadlmayr A, Soloiz M, Tig H, Patsch W, Weiss G, Stickel F, Datz C. A role for low hepatic copper concentrations in nonalcoholic fatty liver disease. Am J Gastroenterol 2010;105:1978–1985.
61. Aigner E, Theurl I, Haufe H, Seifert M, Hohla F, Scharinger L, Stickel F, Mourlane F, Weiss G, Datz C. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008;135:680–688.
62. Nobili V, Siotto M, Bedogni G, Rava L, Pietrobattista A, Panera N, Alisi A, Squitti R. Levels of serum ceruloplasmin associate with pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenter Nutr 2013;56:370–375.
63. Antonucci L, Porcu C, Iannucci G, Balsano C, Barbaro B. Non-alcoholic fatty liver disease and nutritional implications: special focus on copper. Nutrients 2017;9.
64. Lai CC, Huang WH, Klevay LM, Gunning WT 3rd, Chiu TH. Antioxidant enzyme gene transcription in copper-deficient rat liver. Free Radic Biol Med 1996;21:233–240.
65. Lai CC, Huang WH, Askari A, Wang Y, Sarvazyan N, Klevay LM, Chiu TH. Differential regulation of superoxide dismutase in copper-deficient rat organs. Free Radic Biol Med 1994;16:613–620.
66. al-Othman AA, Rosenberg F, Lei KY. Copper deficiency increases in vivo hepatic synthesis of fatty acids, triacylglycerols, and phospholipids in rats. Proc Soc Exp Biol Med 1993;204:97–103.
67. Fields M, Holbrook J, Schofield D, Smith JC Jr, Reiser S. Effect of fructose or starch on copper-67 absorption and excretion by the rat. J Nutr 1986;116:625–632.
68. Church SJ, Begley P, Kureishy N, McHarg S, Bishop PN, Bechtold DA, Unwin RD, Cooper GJ. Deficient copper concentrations in dried-defatted hepatic tissue from ob/ob mice: a potential model for study of defective copper regulation in metabolic liver disease. Biochem Biophys Res Commun 2015;460:549–554.
69. Britton LJ, Subramaniyan VN, Crawford DH. Iron and non-alcoholic fatty liver disease. World J Gastroenterol 2016;22:8112–8122.
70. MacDonald GA, Bridle KR, Ward PJ, Walker N, Hougum K, George DK, Smith JL, Powell LW, Crawford DH, Ramm GA. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J Gastroenterol Hepatol 2001;16:599–606.
71. Ryan JD, Armitage AE, Cobbold JR, Borsani O, Dongiovanni P, Neubauer S, Morovat R, Wang LM, Pasricha SR, Fargion S, Collier J, Barnes E, Drakesmith H, Valenti L, Pavlides M. Hepatic iron is the major determinant of serum ferritin in NAFLD patients. Liver Int 2018;38:164–173.
72. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55:77–85.
73. Britton L, Jaskowski LA, Bridle K, Seendes E, Wallace D, Santramupwala N, Reiling J, Miller G, Mangiafico S, Andrikopoulos S, Subramaniam VN, Crawford D. Ferroportin expression in adipocytes does not contribute to iron homeostasis or metabolic responses to a high calorie diet. Cell Mol Gastroenterol Hepatol 2018;5:319–331.
74. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007;46:1071–1080.
75. Valenti L, Rametta R, D'Onorio P, Motta BM, Canavesi E, Pelusi S, Pulixi EA, Fracanzani AL, Fargion S. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One 2012;7:e48804.
76. Nelson JE, Wilson L, Brun T, Yeh MM, Klein DE, Unalp-Arida A, Kowdley KV. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2011;53:448–457.
77. Valenti L, Fracanzani AL, Bugianesi E, D'Onorio P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S, HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010;138:905–912.
78. Brun T, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–2474.
79. Handa P, Morgan-Stevenson V, Maliken BD, Nelson JE, Washington S, Westerman M, Yeh MM, Kowdley KV. Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. Am J Physiol Gastrointest Liver Physiol 2016;310:G117–G127.
80. Maliken BD, Nelson JE, Klintworth HM, Beauchamp M, Yeh MM, Kowdle KV. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 2013;57:1806–1813.

81. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251–1258.

82. Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, Pulixi EA, Maggioni M, Fargion S. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014;20:3002–3010.

83. Khodadoostan M, Zamanidoost M, Shavakhi A, Sanei H, Shahbazi M, Ahmadian M. Effects of phlebotomy on liver enzymes and histology of patients with nonalcoholic fatty liver disease. Adv Biomed Res 2017;6:12.

84. Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, Ching HL, Kava J, Bynevelt M, MacQuillan GC, Garas G, Ayonrinde OT, Mori TA, Croft KD, Niu X, Jeffrey GP, Olynyk JK. The impact of phlebotomy in nonalcoholic fatty liver disease: a prospective, randomized, controlled trial. Hepatology 2015;61:1555–1564.

85. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahl W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A 1993;90:2160–2164.

86. Issermann I, Prince RA, Tugwood JD, Green S. The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol 1993;11:37–47.

87. Shiota G. Loss of function of retinoic acid in liver leads to steatohepatitis and liver tumor: a NASH animal model. Hepatol Res 2005;33:155–160.

88. Lavigne PM, Karas RH. The current state of niacin in nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251–1258.

89. Green R, Allen LH, Bjorke-Monsen AL, Brito A, Gueant JL, Miller JW, Molloy AM, Nexo E, Stabler S, Toh BH, Ueland PM, Yajnik C. Vitamin B12 deficiency. Nat Rev Dis Primers 2017;3:17040.

90. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009;202:68–75.

91. Ganji SH, Kukes GD, Lambrecht N, Kashyap ML, Kamanna VS. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2014;306:G320–G327.

92. Ganji SH, Kashyap ML, Kamanna VS. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: impact on nonalcoholic fatty liver disease. Metabolism 2015;64:982–990.

93. Hu M, Chu WC, Yamashita S, Yeung DK, Shi L, Wang D, Masuda D, Yang Y, Tomlinson B. Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. J Lipid Res 2012;53:802–809.

94. Polyzos SA, Kontouras J, Patsioura K, Katsiki E, Zafeiriadou E, Zavos C, Deretzi G, Tsiacouisi E, Slavakis A. Serum vitamin B12 and folate levels in patients with nonalcoholic fatty liver disease. Int J Food Sci Nutr 2012;63:659–666.

95. Koplay M, Gulcan E, Ozkan F. Association between serum vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease. J Investig Med 2011;59:1137–1140.

96. Vos MB, Colvin R, Belt P, Mollerson JP, Murray KF, Rosenthal P, Schwimmer JB, Tonascia J, Unalp A, Levine JE. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr 2012;54:90–96.

97. Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol 2006;40:930–935.

98. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485–2490.

99. Skaaby T, Husemøn LL, Borglykke A, Jorgensen T, Thuesen BH, Pisinger C, Schmidt LE, Linneberg A. Vitamin D status, liver enzymes, and incident liver disease and mortality: a general population study. Endocrine 2014;47:213–220.

100. Seo JA, Eun CR, Cho H, Lee SK, Yoo HJ, Kim SG, Choi KM, Baik SH, Choi DS, Yim HJ, Shin C, Kim NH. Low vitamin D status is associated with nonalcoholic fatty liver disease independent of visceral obesity in Korean adults. PLoS One 2013;8:e75197.

101. Jablonski KL, Jovanovich A, Holmen J, Targher G, Patel YA, Henao R, Moylan CA, Guy CD, Piercy DL, Bril F, Maximos M, Portillo-Sanchez P, Biernacki D, Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG. Strong association between nonalcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011;9:85.
105. Liangpunsakul S, Chalasani N. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci 2011;56:2124–2129.

106. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE, Kowdle KV. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012;55:1103–1111.

107. Beilfuss A, Sowa JP, Sydor S, Beste M, Bechmann LP, Schlattjan M, Syn WK, Wedemeyer I, Mathe Z, Jochem G, Gerken G, Gieseler RK, Canbay A. Vitamin D counteracts fibrogenic TGF-beta signalling in human hepatic stellate cells both receptor-dependently and independently. Gut 2015;64:791–799.

108. Erhardt A, Stahl W, Sies H, Lirussi F, Donner A, Beilfuss A, Sowa JP, Sydor S, Beste M, Bechmann LP, Podszun MC, Grebenstein N, Spruss A, Schlueter T. Dietary alpha- and gamma-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. J Nutr Biochem 2010;21:1200–1206.

109. Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, Poli G. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992;308:267–270.

110. Chalasani NP, Sanyal AJ, Kowdle KV, Robuck PR, Hoofnagel J, Kleiner DE, Unalp A, Tonascia J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009;30:88–96.

111. Cao Y, Wang C, Liu J, Liu ZM, Ling WH, Chen YM. Greater serum carotenoid levels associated with lower prevalence of nonalcoholic fatty liver disease in Chinese adults. Sci Rep 2015;5:12951.

112. Ruhl CE, Everhart JE. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology 2003;124:1821–1829.

113. Sugiura M, Nakamura M, Ogawa K, Ikoma Y, Yano M. High serum carotenoids are associated with lower risk for developing elevated serum alanine aminotransferase among Japanese subjects: the Mikkabi cohort study. Br J Nutr 2016;114:1462–1469.

114. Xiaol M, Chen GD, Zeng FF, Qiu R, Shi WQ, Lin JS, Cao Y, Li HB, Ling WH, Chen YM. Higher serum carotenoids associated with improvement of non-alcoholic fatty liver disease in adults: a prospective study. Eur J Nutr March 29, 2018, Epub ahead of print.

115. Seif El-Din SH, El-Lakkyy NM, El-Naggary AA, Hammam OA, Abd El-Latif HA, Ain-Shoka AA, Ebeid FA. Effects of rosuvastatin and/or beta-carotene on non-alcoholic fatty liver in rats. Res Pharm Sci 2015;10:275–287.

116. Kobori M, Ni Y, Takahashi Y, Watanabe N, Sugiura M, Ogawa K, Nagashimada M, Kaneko S, Naito S, Ota T. beta-Cryptoxanthin alleviates diet-induced nonalcoholic steatohepatitis by suppressing inflammatory gene expression in mice. PLoS One 2014;9:e89294.

117. Ni Y, Nagashimada M, Zhan L, Nagata N, Kobori M, Sugiura M, Ogawa K, Kaneko S, Ota T. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, beta-cryptoxanthin. Endocrinology 2015;156:987–999.

118. Chalasani N, Sanyal AJ, McCullough AJ, Dasarathy S. Patients with nonalcoholic fatty liver disease have a low response rate to vitamin D supplementation. J Nutr 2017;147:1938–1946.

119. Miranda-Vilela AL, Akimoto AK, Alves PC, Pereira LC, Goncalves CA, Klautau-Guimaraes MN, Grisolia CK. Dietary carotenoid-rich pequi oil reduces plasma lipid peroxidation and DNA damage in runners and evidence for an association with MnSOD genetic variant -Val9Ala. Genet Mol Res 2009;8:1481–1495.

120. Dasarathy J, Varghese R, Feldman A, Khiyami A, McCullough AJ, Dasarathy S. Patients with nonalcoholic fatty liver disease have a low response rate to vitamin D supplementation. J Nutr 2017;147:1129–1131.

121. Ikeeuchi M, Koyama T, Takahashi J, Yazawa K. Effects of astaxanthin in obese mice fed a high-fat diet. Biosci Biotechnol Biochem 2007;71:893–899.

122. Genet Mol Res 2009;8:1481–1495.
130. Lavine JE, Schwimmer JB, Van Natta ML, Molloston JP, Murray KF, Rosenthal P, Abrams SH, Scheinman AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305:1659–1668.

131. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67:328–357.

132. Blond E, Disse E, Cuerq C, Drai J, Valette PJ, Laville M, Thivolet C, Simon C, Caussy C. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia 2017;60:1218–1222.

133. Venu M, Martin E, Saeian K, Gawrieh S. High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantation. Liver Transplant 2013;19:627–633.

134. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010;51:771–784.

135. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956–965.

136. Pickett-Blakely O, Newberry C. Future therapies in obesity. Gastroenterol Clin North Am 2016;45:705–714.

137. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67:829–846.

138. Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms. Liver Int 2017;37:936–949.

139. Eslamparast T, Tandon P, Raman M. Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease. Nutrients 2017;9.